Yesterday, I wrote about how Dr. Brian J. Druker persuaded Novartis to take a chance on Gleevec – based on good science, not just the economics. That led me to a great quote from another scientist/executive, Trevor Mundel, head of Novartis' Global Drug Development Division.
He said, “Arguing about commercial value is precisely what paralyzes the industry and leads to the destruction of innovation.”
Wednesday, August 05, 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment